Pa. Risperdal Off-Label Trial Ends With Nonsuit For Janssen

PHILADELPHIA - (Mealey's) A Pennsylvania state court judge on June 14 granted Janssen Pharmaceutica Inc.'s motion for a nonsuit of the state government's third-party payer suit alleging that the drug company's off-label marketing of its atypical antipsychotic drug Risperdal resulted in...

West Virginia High Court Vacates $4.47M Judgment; FDA Warning Letters Not Matter Of Law

CHARLESTON, W.Va. -- (Mealey's) The West Virginia Supreme Court of Appeals on Nov. 18 reversed a $4,475,000 consumer law judgment against Johnson & Johnson concerning the marketing of Risperdal and Duragesic after agreeing with the defendant that the judge in a bench trial improperly relied on...

N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease

NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the risk of diabetes but that the atypical antipsychotic...